We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Infection Can Lead to False Negatives for Cerebrospinal Fluid β-2 Transferrin

By LabMedica International staff writers
Posted on 21 Oct 2014
Researchers have found that the presence of Streptococcus pneumoniae in cerebrospinal fluid (CSF) can lead to false-negative β-2 transferrin (β2TRNSF) test results and misdiagnosis that may detrimentally affect healthcare decisions for patients.

Free passage of bacterial flora from the nasal cavity and paranasal sinuses through a CSF fistula into the cranium may pose increased risk for meningitis and encephalitis. More...
Thus, early diagnosis and treatment of CSF leakage could decrease the risk of a lethal infection. Although β2TRNSF is a highly reliable marker for diagnosing cases of CSF leakage (even in CSF contaminated with blood or other secretions)—it has not been examined in the presence of central nervous system bacterial infection.

In a prospective analysis, a team led by Nir Hirshoren, MD, at the Hebrew University School of Medicine–Hadassah Medical Center (Jerusalem, Israel) examined β2TRNSFdetection in artificially contaminated CSF as a research model. Sterile (tested for sterility) CSF was drawn from 9 prospectively-recruited neurosurgical patients. CSF samples were contaminated in vitro by controlled spiking with bacteria, chosen for ability to cause meningeal neurosurgical-related infections: Streptococcus pneumoniae, methicillin-sensitive Staphylococcus aureus (MSSA), Staphylococcus epidermidis, or Pseudomonas aeruginosa.

β2TRNSF analysis was performed using qualitative immunoblotting electrophoresis and quantitative enzyme-linked immunosorbent assay (ELISA). Two time points were examined, following immediate inoculation (t0 ) and following an overnight incubation (t18 ), over various bacterial-load concentrations. In this study, only S. pneumoniae was observed to significantly affect β2TRNSF detection. At both the t0 and t18 time points following S. pneumoniae inoculation, β2TRNSF was not detected when immunoblotting electrophoresis was used; quantitative analysis using ELISA demonstrated significant β2TRNSF concentration decrease.

A secondary objective of the study was to explore whether the disappearance of β2TRNSF in the assays is due to a passive or active mechanism. The researchers suspected that in some cases of bacterial infections, β2TRNSF might be adsorbed, degraded, or consumed by bacteria. CSF inoculated with S. pneumoniae was also examined in the presence of the non-cell-wall antibiotic ciprofloxacin, which led to the same results. Since β2TRNSF detection decreased also with inactivated (i.e. + ciprofloxacin) S. pneumoniae, a passive process was suggested, possibly due to adsorption via distinctive features of the S. pneumoniae cell wall not present in the other species examined.

The authors note that although the study was limited by a small sample number (n=9), potential bias was largely overcome by exploring different bacterial loads, examining diverse clinical bacterial species, and using two reliable assays. Further investigation in the clinical setting is needed, however the results indicate that, in the presence of a S. pneumoniae cerebral nervous system infection, using a β2TRNSF test for CFS leak detection may be deceiving and should be interpreted cautiously.

The authors further caution that the importance of β2TRNSF assays is limited to borderline, clinical-uncertainty cases. In other cases, a β2TRNSF negative result may not change a clinical decision regardless of CSF S. pneumoniae presence, and appropriate imaging modalities and surgery may be warranted anyway.

The study was reported by Korem M. et al. in the journal Laryngoscope, September 29, 2014, online ahead of print.

Related Links:

Hebrew University School of Medicine – Hadassah Medical Center
Hebrew University Hadassah Medical School



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.